All Stories

Biohaven’s biopolar candidate fails to improve mania in pivotal trial

Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial.

Mar 4, 2025 - 08:57
 0
Biohaven’s biopolar candidate fails to improve mania in pivotal trial
Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial.
Read More

Tags:

Previous Article

Vingroup and global investment firm JTA Investment Qatar signed MOU for strategi...

Next Article

Breakfast costs climb as shop price inflation records biggest monthly jump

Related Posts

Fierce Biotech Fundraising Tracker '25: Abcuro raises $200M; AdvanCell adds on $112M

Fierce Biotech Fundraising Tracker '25: Abcuro raises $...

Feb 12, 2025  0

Oligonucleotide stops gene expansion process that drives Huntington's disease: study

Oligonucleotide stops gene expansion process that drive...

Feb 12, 2025  0

Flourish Research makes deal with Diablo to acquire the California-based clinical research facility

Flourish Research makes deal with Diablo to acquire the...

Feb 20, 2025  0